Empagliflozin and dapagliflozin show similar effectiveness in preventing cardiorenal outcomes among patients with type 2 ...

Children aged 10 years and older with type 2 diabetes can now improve their glycemic control with a drug previously only approved for adults. After 26 weeks of treatment, results showed that ...

Review the side-effects of Dapagliflozin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

The sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin (Farxiga) met its primary endpoint in the DELIVER phase III trial by significantly lowering the risk of cardiovascular death or ...

Bristol-Myers Squibb and AstraZeneca announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin demonstrated significant reductions in HbA1C compared with ...

Researchers found that 53% of the 78 participants in the dapagliflozin group and 30% of the 76 participants in the placebo group had MASH improvement without worsening of fibrosis. HealthDay News — ...

Please provide your email address to receive an email when new articles are posted on . Compared with placebo, dapagliflozin reduced risk for ventricular arrhythmias, cardiac arrest and sudden death, ...

Objectives: The efficacy of dapagliflozin as add-on therapy to metformin has been assessed in randomized trials. However, its effectiveness has not been assessed in a US real-world setting. Methods: ...

PHILADELPHIA, PA—Dapagliflozin (Farxiga; AstraZeneca), originally developed for the treatment of type 2 diabetes, has a broad, positive impact across various subsets of patients with chronic heart ...

Please provide your email address to receive an email when new articles are posted on . NATIONAL HARBOR, Md. — In a DELIVER subgroup analysis, dapagliflozin conferred similar benefit in patients with ...

The appraisal committee reviewed the data available on the clinical and cost effectiveness of dapagliflozin, having considered evidence on the nature of type 2 diabetes and the value placed on the ...